iX Biopharma (SGX:42C) Payments of Debt: S$-1.17 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:42C iX Biopharma Ltd SGX:42C
37 GF Score
Price S$0.54
! 2 Warning Signs
View Full Analysis

What is iX Biopharma Payments of Debt?

iX Biopharma SGX:42C +5.88% 37 Payments of Debt is S$-1.17 Mil as of Jun. 2026. GuruFocus rates SGX:42C with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

iX Biopharma's Payments of Debt for the three months ended in Jun. 2026 was S$-0.40 Mil.

iX Biopharma's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was S$-1.17 Mil.

iX Biopharma Payments of Debt Related Terms

iX Biopharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for iX Biopharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iX Biopharma Payments of Debt Chart

iX Biopharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.65 -0.60 -1.14 -0.59 -1.35

iX Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.04 0.00 -0.77 -0.40
SGX:42C
37GF Score
iX Biopharma Ltd SGX:42C
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iX Biopharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of S$-1.17 Mil mean?
iX Biopharma (SGX:42C) has a Payments of Debt of S$-1.17 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on iX Biopharma and its competitors.
Is iX Biopharma's Payments of Debt too high?
iX Biopharma's current Payments of Debt is S$-1.17 Mil. Overall, iX Biopharma has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Payments of Debt compare to ZTS and UTHR?
iX Biopharma's Payments of Debt of S$-1.17 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on iX Biopharma and its competitors. iX Biopharma's current Payments of Debt is S$-1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
iX Biopharma (SGX:42C) has a current Payments of Debt of S$-1.17 Mil. The current Payments of Debt is S$-1.17 Mil. iX Biopharma's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Payments of Debt is S$-1.17 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iX Biopharma Business Description

Address 1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
37GF Score

Get the complete analysis for SGX:42C

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.54
Price